Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Diagnostic Value Of Fibulin-3 For Malignant Pleural Mesothelioma: A Systematic Review And Meta-analysis

Ran Ren, P. Yin, Y. Zhang, J. Zhou, Yixing Zhou, R. Xu, Hai Lin, C. Huang
Published 2016 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Background Several studies have investigated the diagnostic value of fibulin-3 for malignant pleural mesothelioma (MPM), but the results were various. Therefore, we performed a systematic review and meta-analysis to evaluate the diagnostic value of fibulin-3 for MPM. Results Eight studies were included in this work. The overall sensitivity of blood fibulin-3 were 0.87 (95% CI, 0.58 – 0.97) and 0.89 (95% CI, 0.77 – 0.95), respectively. The overall sensitivity and specificity of PF fibulin-3 for MPM were 0.73 (95% CI, 0.54 – 0.86) and 0.80 (95% CI, 0.60 – 0.91), respectively. The area under curve of blood and pleural effusion (PF) Fibulin-3 were 0.94 (95% CI, 0.91 – 0.96) 0.83 (95% CI, 0.79 – 0.86), respectively. Methods PubMed and EMBASE databases were searched up to July 29, 2016 to verify studies investigating the diagnostic value of fibulin-3 for MPM. The quality of eligible studies was assessed using the revised Quality Assessment for Studies of Diagnostic Accuracy tool (QUADAS-2). The overall sensitivity and specificity were pooled using a bivariate model. Conclusion Fibuoin-3 is a useful diagnostic marker for MPM.
This paper references
10.7326/0003-4819-155-8-201110180-00009
QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies
P. Whiting (2011)
10.1158/1078-0432.CCR-15-1130
HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
A. Napolitano (2016)
10.1016/j.ctrv.2015.05.001
The established and future biomarkers of malignant pleural mesothelioma.
V. Panou (2015)
10.1002/SIM.1099
Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data.
S. Walter (2002)
10.1016/J.EJCDT.2013.10.004
Role of fibulin-3 in the diagnosis of malignant mesothelioma
M. Agha (2014)
10.1136/bmjopen-2013-004145
Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
Ai Cui (2014)
10.1111/1469-0691.12474
Systematic reviews and meta-analyses of diagnostic test accuracy.
M. Leeflang (2014)
10.1136/thoraxjnl-2014-205205
Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
J. Creaney (2014)
10.1016/j.jtho.2016.04.028
Consensus Report of the 2015 Weinman International Conference on Mesothelioma
M. Carbone (2016)
10.7314/APJCP.2015.16.4.1403
Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma.
H. Kaya (2015)
Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis.
H. Lin (2014)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.1007/s00408-016-9868-1
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure
Melike Demir (2016)
10.1200/JCO.2011.39.6671
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
Incidence and survival trends for Oncotarget 84858 www.impactjournals.com/oncotarget malignant pleural and peritoneal mesothelioma
Mj Soeberg (1982)
10.1038/bjc.2015.286
Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
M. Kirschner (2015)
10.1016/J.JCLINEPI.2005.01.016
The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed.
J. Deeks (2005)
10.3978/j.issn.2305-5839.2015.07.03
Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.
Weiquan Zhang (2015)
10.21037/atm.2016.03.17
Perspective on malignant pleural mesothelioma diagnosis and treatment.
Ori Wald (2016)
10.1016/J.YPAT.2012.10.023
Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma
A. McCullough (2013)
Incidence and survival trends for Oncotarget 84858 www.impactjournals.com/oncotarget malignant pleural and peritoneal mesothelioma, Australia, 1982-2009
MJ Soeberg (2016)
10.1016/J.EJCDT.2014.08.001
Value of plasma and pleural effusion fibulin-3 levels in the diagnosis of malignant pleural mesothelioma effusions
A. Elgazzar (2014)
10.1016/j.cca.2014.02.024
Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis.
Z. Hu (2014)
10.1056/NEJMoa1115050
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
H. Pass (2012)
10.1373/CLINCHEM.2005.048595
Case-control and two-gate designs in diagnostic accuracy studies.
A. Rutjes (2005)
10.1016/J.JCLINEPI.2005.02.022
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews.
J. Reitsma (2005)
Incidence and survival trends for malignant pleural and peritoneal mesothelioma
M J Soeberg (1982)
10.1097/MCP.0000000000000167
Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma
J. Creaney (2015)
10.1177/107327480601300402
Malignant pleural mesothelioma: a comprehensive review.
R. Ismail-Khan (2006)
10.1371/journal.pone.0134376
Diagnostic Accuracy of Natriuretic Peptides for Heart Failure in Patients with Pleural Effusion: A Systematic Review and Updated Meta-Analysis
Zhi-jun Han (2015)
Preferred reporting items for systematic reviews and Oncotarget 84859 www.impactjournals.com/oncotarget meta-analyses: the PRISMA statement
D Moher (2009)
Preferred reporting items for systematic reviews and www.impactjournals.com/oncotarget meta-analyses: the PRISMA statement
D Moher (2009)



This paper is referenced by
10.3390/cancers10060203
Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on
C. Ledda (2018)
10.1007/s12253-019-00751-9
Monoclonal Caveolin 1 Expression in the Differential Diagnosis of Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma: Is it Useful?
Zehra Bozdağ (2019)
10.4225/23/5976d9b9cabf2
The diagnostic potential and biological significance of MicroRNA in Malignant Pleural Mesothelioma
Kimberly A. Birnie (2016)
10.5772/intechopen.89438
Asbestos-Related Diseases and Blood Biomarkers
A. Franko (2019)
10.1016/j.envres.2017.03.055
Analysis of fibulin‐3 after exposure to asbestos‐like fibers
V. Rapisarda (2017)
10.18632/oncotarget.20409
Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma
Kimberly A. Birnie (2017)
10.1111/1759-7714.13746
Diagnostic value of microRNAs for malignant pleural mesothelioma: A mini‐review
Yan-qiu Han (2020)
10.3390/ijms19092787
Extracellular Interactions between Fibulins and Transforming Growth Factor (TGF)-β in Physiological and Pathological Conditions
T. Tsuda (2018)
10.1016/j.ebiom.2020.103031
A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma
Bill T V Duong (2020)
10.1177/1753466618808660
Biomarkers in the diagnosis of pleural diseases: a 2018 update
J. M. Porcel (2018)
10.1093/carcin/bgz103
Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Christina Gillezeau (2019)
10.1007/s12253-020-00793-4
Correction to: Monoclonal Caveolin 1 Expression in the Differential Diagnosis of Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma: Is it Useful?
Zehra Bozdağ (2020)
10.1155/2019/8628612
MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions
Kimberly A. Birnie (2019)
10.1038/s41598-020-62388-y
Validation of Calprotectin As a Novel Biomarker For The Diagnosis of Pleural Effusion: a Multicentre Trial
M. Botana-Rial (2020)
10.18632/oncotarget.19041
Diagnostic value of D2-40 immunostaining for malignant mesothelioma: a meta-analysis.
C. He (2017)
10.1007/978-3-030-24725-6_4
Lung Cancer Biomarkers in Proximal Fluids
Gabriel D. Dakubo (2019)
10.1177/0004563217741145
Biomarkers in mesothelioma
D. Arnold (2018)
10.1042/BSR20203097
Circulating and local nuclear expression of survivin and fibulin-3 genes in discriminating benign from malignant respiratory diseases: correlation analysis
M. Hassan (2020)
Semantic Scholar Logo Some data provided by SemanticScholar